VRX
$15.46
Valeant Pharmaceuticals Intl
$.02
.13%
VRX
Earnings Whisper ®
N/A
4th Quarter December 2016
Consensus:  $1.34
Revenue:  $2.38 Bil
Tuesday
Feb 7
6:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Tuesday, November 08, 2016

What do you expect when VRX reports earnings?
Beat
Meet
Miss

Where is VRX's stock price going from here?
Up
Flat
Down
Stock chart of VRX
Analysts
Summary of analysts' recommendations for VRX
Score
Grade
Pivots
Resistance
$16.32
$16.11
$15.78

$15.57

Support
$15.24
$15.03
$14.70
Tweet
Growth
Description
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant's development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.
Peers
Endo International plcJohnson & JohnsonCelgeneBristol-Myers SquibbBioMarin PharmaceuticalEli LillyPfizerRegeneron PharmaceuticalsPerrigoVertex Pharmaceuticals